Immutep is listed on the Australian Stock Exchange (ASX:IMM) and on the NASDAQ Global Market (NASDAQ:IMMP) in the U.S. (ADR's).
We are a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, with operations in Europe, Australia, and the U.S.
We are the global leader in the understanding of and in the development of therapeutics that modulate Lymphocyte Activation Gene-3 (“LAG-3”), a cell surface molecule which plays a vital role in regulating T cells and which was discovered by our Chief Scientific Officer and Chief Medical Officer Dr. Frederic Triebel.
Our objective is to harness and strengthen the power of patients’ immune systems through therapeutic intervention for the benefit of patients’ health. We have one pre-clinical and three clinical LAG-3 product candidates under development, including two antibodies for modulating immune responses in autoimmunity and cancer, through pharmaceutical partnerships, with Novartis and GlaxoSmithKline.
Our lead product candidate is eftilagimod alpha (LAG-3Ig or IMP321), a first-in-class antigen presenting cell (APC) activator currently being investigated in clinical trials as a treatment (in combination with chemotherapy or immune therapy) for breast cancer and melanoma.
Latest Media Releases
22/07/2024 08:12:00
-- Final discussion with the FDA, successfully concluding the regulatory preparations for the TACTI-004 Phase III trial design to evaluate efti in combination with KEYTRUDA® (pembrolizumab), MSD…
12/07/2024 08:48:00
Efti in combination with KEYTRUDA® (pembrolizumab) achieved a 35.5% response rate in evaluable patients (N=31), according to RECIST 1.1, among the highest recorded for a treatmen…
Latest News
Company News /
by Peter Milios -
5 days ago
22 Jul 2024 - Immutep (ASX:IMM; NASDAQ:IMMP), a leading biotechnology firm specialising in LAG-3 immunotherapy, has achieved a significant milestone in its quest to redefine cancer…
Company News /
by Abbey Phillipps -
3 months ago
18 Apr 2024 - A snapshot of the stocks on the move, featuring Nimy Resources, New Age Exploration and Immutep.
Interviews /
by Manny Anton -
4 months ago
25 Mar 2024 - Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt provides an update on the company's pipeline of clinical trials, focusing on results in head and neck …
Company News /
by Abbey Phillipps -
8 months ago
09 Nov 2023 - A snapshot of the stocks on the move, featuring Sunstone Metals (ASX:STM), Immutep (ASX:IMM, NASDAQ:IMMP), European Metals Holdings (ASX:EMH & AIM:EMH) and QX Resourc…
Interviews /
by Paul Sanger -
8 months ago
31 Oct 2023 - Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses progress of the company's drug candidates, highlighting promising data from the 2023 ESMO Co…
Company News /
by Abbey Phillipps -
9 months ago
23 Oct 2023 - A snapshot of the stocks on the move, featuring Immutep (ASX:IMM; NASDAQ:IMMP), Chimeric Therapeutics (ASX:CHM) and Sayona Mining (ASX:SYA; OTCQB:SYAXF).
Company News /
by Peter Milios -
11 months ago
31 Jul 2023 - Immunotherapy company Immutep has released its Quarterly Activities report, which highlights significant progress in late-stage and registrational trials.
Market Reports /
by Peter Milios -
A year ago
28 Jul 2023 - Australian retail sales experienced a 0.8% decline last month, as reported by the Australian Bureau of Statistics. This result came as a surprise to markets, which ha…
Company News /
by Peter Milios -
A year ago
20 Jun 2023 - Immutep Limited (ASX:IMM), a clinical-stage biotechnology company focusing on LAG-3 immunotherapies for cancer and autoimmune diseases, has received a new patent from…